Subscribe
shutterstock_1732246315_repelsteeltje
Repelsteeltje / Shutterstock.com
29 September 2020AmericasSarah Morgan

Appeals court sides with Pfizer, Merck KGaA in $5bn suit

The US Court of Appeals for the Federal Circuit has sided with EMD  Serono and Pfizer over the invalidation of a multiple sclerosis (MS) drug patent, in a defeat for biotech company Biogen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
MSD secures victory before English court
20 October 2020   The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
MSD secures victory before English court
20 October 2020   The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
MSD secures victory before English court
20 October 2020   The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner